As part of our on-going #SHARETHESCIENCE series, Save the Cord Foundation and Mediware, Inc. are proud to welcome Dr. Colleen Delaney who will speak about the possible clinical applications of expanded cord blood progenitor cells.
As the scientific founder and chief medical officer of Nohla Therapeutics, Inc., Dr. Delaney’s research interests focus on the role of the Notch signaling pathway in hematopoietic stem cell regulation and ex-vivo expansion of umbilical cord blood stem and progenitor cells for clinical applications.
The success of her research led to the establishment of Nohla which is a cellular therapy company focused on developing off-the-shelf, universal donor therapies that require no HLA matching. Her group has developed a novel and clinically feasible method for the ex vivo expansion of cord blood derived hematopoietic stem and progenitor cells in the presence of Notch ligands. This work was translated into a novel pilot study investigating the use of ex vivo expanded cord blood progenitors to augment conventional cord blood transplantation.
She has since extended this work to investigate the potential of cryopreserved, non-HLA matched “off-the-shelf” ex vivo expanded cord blood progenitor cells to provide rapid but transient myeloid reconstitution in the setting of cord blood transplant and following dose-intensive chemotherapy.
For this Share the Science webinar, Dr. Delaney discusses methods for expanding cord blood stem and progenitor cells, and the clinical application of these cells for cord blood transplant and chemotherapy-induced neutropenia.
Dr. Colleen Delaney from NoHLA Therapeutics
“Clinical Applications for Expanded Cord Blood Progenitor Cells”
RECORDED: Wednesday, December 14th: Noon – 1 p.m. central time
Webinar: Free to register. Open to the public.
Cord blood is an effective and widely used source of stem cells for patients undergoing hematopoietic stem cell transplant for hematologic malignancies. While cord blood offers some distinct advantages over conventional stem cell sources, delayed engraftment due to the low cell dose available in each unit continues to be a challenge in the transplant setting. This webinar will cover development and clinical translation of methodologies for the ex vivo expansion of cord blood stem and progenitor cells.
Dr. Delaney will also discuss the clinical use of expanded cord blood progenitors, which has been shown to be safe in the settings of hematopoietic transplant and dose-intensive chemotherapy. In the cord blood transplant setting, use of these expanded cells has been shown to reduce time to neutrophil and platelet recovery as well as being associated with less severe acute GVHD. In the setting of chemotherapy-induced neutropenia, expanded cells have been shown to decrease the rate of documented infection.
* * *
We wish to thank Dr. Delaney for volunteering her time to speak on Share the Science and sharing her valuable insight on cord blood.
We also wish to thank our generous sponsors, Mediware Inc., who continue to support cord blood education through our “Share the Science” series.
Discover the full Share the Science series and view archived webinars highlighting the latest cord blood research.